Therapeutic Areas of Focus

With the Company’s novel therapeutics, Nanocan seeks to transform treatments for certain cancers. Nanocan’s initial products for rollout will target pancreatic cancer, lung cancer, and cervical cancer:

  • Pancreatic Cancer: One of the deadliest forms of cancer with limited treatment options. According to the National Cancer Institute, the 5-year relative survival rate for pancreatic cancer patients is 10%. It’s estimated there will be 57,600 new pancreatic cancer cases in the U.S. in 2020, with over 47,000 deaths. The World Health Organization (WHO) estimates there were 458,000 new cases of pancreatic cancer globally in 2018, with 432,000 deaths. Nanocan has preclinical data showing promising results for a potential safe and effective therapeutic for this most deadliest form of cancer.
  • Lung Cancer: One of the most common forms of cancer. According to the American Cancer Society, lung cancer is the leading cancer death among both men and women, making up almost 25% of all cancer death. In 2020, nearly 230,000 people will be diagnosed with lung cancer in the U.S. with over 135,000 deaths. In 2018, according to the WHO over 2 million people were diagnosed with lung cancer worldwide with 1.7 million deaths.
  • Cervical Cancer: When detected at an early stage, the 5-year survival rate for cervical cancer is over 90%. Low and Middle Income Countries (“LMICs”) and other low-resource settings have inadequate cervical cancer screening which leads to higher cancer disparities and deaths. According to the WHO over 570,000 persons will be diagnosed with cervical cancer worldwide with over 311,000 deaths in 2020. Nanocan has partnerships with leading cancer treatment centers in Africa and is mapping out multicenter clinical trials for cervical cancer in LMICs.

Nanocan’s next tier of products for rollout will target:

  • Breast Cancer
  • Glioblastoma
  • Liver Cancer
  • Prostate Cancer

Additionally, given the potential effectiveness of the Company’s nanoparticle drone delivery technology in combination with certain drug payloads, including phytomedicines, Nanocan is investigating its therapeutics for the treatment of certain respiratory diseases, including COVID-19.

Copyright © 2021 Nanocan Therapeutics Corporation - All Rights Reserved.